Protons against cancer: New research beamline for innovative radiotherapies
Prof. Dr Judith Reindl and PhD student Aikaterini Rousseti (from left to right) from the University of the Bundeswehr Munich present the experimental station for biological samples which is installed at the new Minibee beamline at HZB. © Kevin Fuchs / HZB
Magnetic quadrupoles focus the proton beam in front of the experiment platform. © Kevin Fuchs / HZB
Together with the University of the Bundeswehr Munich, the HZB has set up a new beamline for preclinical research. It will enable experiments on biological samples on innovative radiation therapies with protons.
The proton accelerator at the Helmholtz-Zentrum Berlin (HZB) has been used for about 25 years to combat certain types of eye tumours. So far, over 4800 people have benefited from proton eye tumour therapy, which is carried out in collaboration with Charité – Universitätsmedizin Berlin.
Now, the proton accelerator at HZB also offers the option of conducting preclinical research: A mini-beamline for preclinical experiments (Minibee) has been set up for this purpose together with the University of the Bundeswehr in Munich. The HZB's Proton Therapy Department has built the beam guidance and control system for the minibeams. The University of the Bundeswehr in Munich, with Prof. Judith Reindl from the Institute of Applied Physics and Measurement Technology and the Section of Biomedical Radiation Physics, installed a platform for image-guided irradiation of biological samples. This will enable joint experiments on radiobiology and innovative radiation therapy in the future.
‘At Minibee, we can use medical research to investigate how changes in parameters and settings of the proton beam affect the treatment,’ says Judith Reindl. Among other things, Minibee is designed to generate ultrashort proton flashes (FLASH therapy) or needle-fine radiation (beamlets). ‘Our aim is to develop new methods that effectively destroy tumours while providing even better protection for healthy tissue,’ says Prof. Dr. Andrea Denker, head of the Department of Proton Therapy at HZB.
- Less is more: Why an economical Iridium catalyst works so wellIridium-based catalysts are needed to produce hydrogen using water electrolysis. Now, a team at HZB has shown that the newly developed P2X catalyst, which requires only a quarter of the Iridium, is as efficient and stable over time as the best commercial catalyst. Measurements at BESSY II have now revealed how the special chemical environment in the P2X catalyst during electrolysis promotes the oxygen evolution reaction during water splitting.
- Battery research with the HZB X-ray microscopeNew cathode materials are being developed to further increase the capacity of lithium batteries. Multilayer lithium-rich transition metal oxides (LRTMOs) offer particularly high energy density. However, their capacity decreases with each charging cycle due to structural and chemical changes. Using X-ray methods at BESSY II, teams from several Chinese research institutions have now investigated these changes for the first time with highest precision: at the unique X-ray microscope, they were able to observe morphological and structural developments on the nanometre scale and also clarify chemical changes.
- Hydrogen: Breakthrough in alkaline membrane electrolysersA team from the Technical University of Berlin, HZB, IMTEK (University of Freiburg) and Siemens Energy has developed a highly efficient alkaline membrane electrolyser that approaches the performance of established PEM electrolysers. What makes this achievement remarkable is the use of inexpensive nickel compounds for the anode catalyst, replacing costly and rare iridium. At BESSY II, the team was able to elucidate the catalytic processes in detail using operando measurements, and a theory team (USA, Singapore) provided a consistent molecular description. In Freiburg, prototype cells were built using a new coating process and tested in operation. The results have been published in the prestigious journal Nature Catalysis.